Spirulina plantensis supplementation reduces anemia, inflammation and improve nutritional status of sickle cell aneamia patients
Not Applicable
- Conditions
- Haematological Disorders
- Registration Number
- PACTR202211821139161
- Lead Sponsor
- PIEME Constant Anatole
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Will be included in this study
1-Homozygote (SS) and heterozygote SC and SF
2- Male or female
3-Aged between 2 – 35 Years old
4- Patients who approve and sign the form
Exclusion Criteria
1-Sickle cell patient whose iron blood level is higher than normal
2-Sickle cell patient who is taking other treatment simultaneously
3- Sickle cell patient who decided to withdraw to the study
4- Sickle cell patient who did not go through the supplementation at least 3 three and half months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Spirulina plantensis's effects on sickle cell anemia pathophysiology?
How does Spirulina plantensis supplementation compare to standard-of-care treatments for sickle cell anemia in reducing anemia and inflammation?
Are there specific biomarkers that predict response to Spirulina plantensis in sickle cell anemia patients?
What are the potential adverse events associated with Spirulina plantensis supplementation in sickle cell anemia patients?
What combination therapies or alternative supplements show promise in improving nutritional status and reducing inflammation in sickle cell disease?